Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse
Clinical trial NCT07595965 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07595965
- Sponsor
- Corestemchemon, Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-12-01
- Primary completion
- 2027-12-30
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.